DecImmune Therapeutics, a US-based healthcare company, has raised $1m in its series B round led by Astellas Venture Management, the corporate venturing division of Japan-based pharmaceutical company Astellas.
Janis Naeve, director of Amgen Ventures, the corporate venturing unit of US peer Amgen, was also named in the regulatory filing as a backer of DecImmune’s second round. The final member of the consortium was venture capital firm HealthCare Ventures.
The consortium invested $1.1m, of which Astellas provided $1m, while the US National Institutes of Health gave $2.2m in a grant.
Shinya Yano, president of Astellas Venture Management, said: "DecImmune’s approach to inhibiting damage caused by acute inflammatory response without deactivating important elements of the immune system is quite unique."
In September 2006, DecImmune raised $2.1m in its series A round, according to a regulatory filing seen by news provider PEWeek.